The interplay between prolactin and cardiovascular disease.

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Metabolic Disorders

Background:

• Hyperprolactinemia's effects on the hypothalamic-pituitary-gonadal axis are known.
• Emerging evidence suggests a link between hyperprolactinemia and increased cardiovascular disease (CVD) risk.
• Conflicting data exists regarding prolactin (PRL) levels and CVD risk or mortality.

Purpose of the Study:

• To investigate the association between hyperprolactinemia and cardiovascular disease (CVD) risk.
• To explore the metabolic effects of hyperprolactinemia and dopamine agonist (DA) treatment on vascular parameters.
• To elucidate potential mechanisms linking hyperprolactinemia to CVD.

Main Methods:

• Review of existing studies on hyperprolactinemia, prolactinoma, and CVD risk.
• Analysis of data on lipid profiles, endothelial function, and inflammatory markers in patients on DA treatment.
• Examination of correlations between prolactin levels, blood pressure, arterial function, and metabolic markers.

Main Results:

• Dopamine agonist (DA) treatment in men with prolactinoma decreased total and LDL-cholesterol.
• DA treatment also showed potential benefits like increased HDL, decreased triglycerides, and improved endothelial function.
• Hyperprolactinemia was associated with increased blood pressure and impaired endothelial function, while DA withdrawal worsened vascular parameters.

Conclusions:

• Hyperprolactinemia is linked to impaired endothelial function and potentially increased CVD risk.
• Dopamine agonist treatment may improve vascular parameters and reduce CVD risk in hyperprolactinemic patients.
• Further research is needed to confirm CVD risk in hyperprolactinemic patients and guide treatment decisions beyond hypogonadism.